/
Embecta Corp. (also referred to herein as "Embecta") is a leading global medical device company, primarily focused on providing solutions to improve the health and well-being of people living with diabetes. All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the cont…
22.41% operating margin is above average. ROIC at 13.09%.
Revenue declined 3.8% YoY. Margins deteriorated 3.5pp alongside, both lines moving the wrong way.
Net debt of $1.22B represents 6.7x FCF, leverage limits flexibility. Operating margin contracted 3.5pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$1.04B
▼ -3.8% YoY
Net Income (TTM)
$112M
▲ +21.8% YoY
Op. Margin
26.86%
▼ -3.5pp YoY
ROIC
15.47%
▼ -0.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$205M
▲ +816.6% YoY
Op. Cash Flow (TTM)
$214M
▲ +437.0% YoY
Net Debt
$1.19B
Cash & Equiv.
$185M
5Y CAGR: -0.1%
5Y CAGR: -16.8%
Continue Research